|

BCMA CART Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Institute of Hematology & Blood Diseases Hospital, China1

Indications

  • R2-ISS-IV /MPSS-IV1
  • Non Paraosseous Extramedullary Infiltration1
  • Early Progression1
  • Primary Refractory1
  • Cytogenetics Ultra High Risk1

Other1 trial

Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.